- Open Access
Expression of EBV Encoded viral RNA 1, 2 and anti-inflammatory Cytokine (interleukin-10) in FFPE lymphoma specimens: a preliminary study for diagnostic implication in Pakistan
© Sheikh and Qadri; licensee BioMed Central Ltd. 2011
- Received: 24 March 2011
- Accepted: 27 July 2011
- Published: 27 July 2011
Epstein Barr Virus (EBV) plays a significant role as a cofactor in the process of tumorigenesis and has consistently been associated with a variety of malignancies. EBV encoded RNAs (EBER1 and EBER2) are the most abundant viral transcripts in latently EBV-infected cells and their role in viral infection is still unclear. Formalin Fixed Paraffin Embedded (FFPE) tissues of surgically removed carcinoma biopsies are widely available form but have never been exploited for expressional studies previously in Pakistan. Immunohistochemistry (IHC) and in situ hybridization (ISH) in FFPE biopsy tissues remains the gold standard for proving EBV relationship in a histopathological lesion but their reagents associated limitations confines their reliability in some applications. Recently introduced targeted drug delivery systems induce viral lytic gene expression and therefore require more sensitive method to quantify viral as well as cellular gene expression.
Eight (8) lymphoma samples were screened to detect the EBV genome. Qualitative and quantitative expression of EBV Encoded RNAs (EBER1, EBER2) and anti-inflammatory cytokine (interleukin-10) in FFPE EBV positive lymphoma tissue samples were then analysed by using Reverse transcriptase Polymerase Chain Reaction (RT-PCR) and Real Time Polymerase Chain Reaction (qRT-PCR), respectively.
In this study we have successfully quantified elevated expressional levels of both cellular and viral transcripts, namely EBER1, EBER2 and anti-inflammatory cytokine (IL-10) in the FFPE Burkitt's lymphoma (BL) specimens of Pakistani origin.
These results indicate that FFPE samples may retain viral as well as cellular RNA expression information at detectable level. To our knowledge, this is first study which represents elevated expressional levels of EBER1, EBER2 and IL-10 in FFPE tissue samples of Burkitt's lymphoma in Pakistan. These observations will potentially improve current lacunas in clinical as well as diagnostic practices in Pakistan and can be further exploited to develop new strategies for studying cellular and/or viral gene expression.
- Epstein Barr Virus
- Epstein Barr Virus Nuclear Antigen
- Latent Epstein Barr Virus
- Lymphoma Sample
- Acute Epstein Barr Virus Infection
Epstein-Barr virus (EBV)  is a ubiquitous human γ-herpes virus infecting more than 90% of the population worldwide  and plays a significant role as a cofactor in the process of tumorogenesis. It has consistently been associated with a variety of malignancies including endemic Burkitt's lymphoma (BL) [1, 2], nasopharyngeal carcinoma [3, 4], T-cell lymphoma, Pyothorax-associated or methotrexate-associated B-cell lymphoma, Primary effusion lymphoma, gastric carcinoma , EBV associated hemophagocytic syndrome and approximately 50% of Hodgkin's diseases. Moreover it has been associated with different types of lymphoproliferative diseases especially in immunocompromised patients . In immunocompromised patients with impaired cell mediated immunity, acute EBV infection is associated with the development of lymphoproliferative disease, with mortality rates between 50-80%. In addition to that, recipients of solid organ transplants, the incidence of post transplant lymphoproliferative disease (PTLD) ranges from 1% to 15% . Prevalence of EBV in Pakistani Burkitt's lymphoma patients is 80% which is significantly higher than in BL in North America .
EBV replicates in the epithelial cells of the mouth, tongue, salivary glands, and oral cavity and then it spread into the B-cells which are the main host cell type for its latent infection . Upon entry into B cell, the EBV proteins are expressed in a cascade manner. Every EBV-transformed cell carries multiple extrachromosomal copies of the viral episome and constitutively expresses a limited set of viral gene products referred to as latent proteins, which comprise of: Six (6) EBV nuclear antigens (EBNAs 1, 2, 3A, 3B, 3C and -LP) [9–11], three latent membrane proteins (LMPs 1, 2A and 2B) and transcripts from the Bam HIA region of the viral genome namely BART transcripts [11, 12]. In addition to the latent proteins, EBV-transformed cell also show abundant expression of the small, non-polyadenylated non-coding RNAs, EBER1 and EBER2. This pattern of latent EBV gene expression, which appears to be activated only in Burkitt's lymphoma, is referred to as 'latency I' [9–13]. Interleukin-10 (IL-10) an anti-inflammatory cytokine (also known as human Cytokine Synthesis Inhibitory Factor (CSIF)), is known to be an important regulator in cell transformation . EBV+ (positive) Burkitt's lymphoma (BL) cells express high level of IL-10 as compared to the EBV- (negative) BL cell lines . On the other hand, the expressional levels of IL-10 are extremely low and/or negligible in normal tumour cell lines [15, 16]. Approximately 10 fold increased expression of the IL-10 in Burkitt's lymphoma cell lines is reported . These elevated levels of EBER and IL-10 have also been known to increase cell's tumorigenicity [17, 18]. This expression profile could be used as power full tool in the expressional profiling studies as well as relative quantification of EBERs in the tissue samples.
For tissue preservation, formalin fixation followed by paraffin wax embedding is mostly used to maintain the morphological features of the original tissue . The Formalin Fixed and Paraffin Embedded (FFPE) tissues are used in various immunohistochemistry (IHC) techniques for localizing Epstein-Barr viral nucleic acid and/or protein to the tumour cells. Previously EBER in-situ hybridization (ISH) was considered as the most excellent test for detection and localization of latent EBV in tissue samples [20, 21]. Other techniques including automated EBER ISH and automated LMP-1 IHC with increased sensitivity and specificity have recently became useful diagnosis tool for EBV related diseases [22–24].
ISH reagents associated limitations like limited target site accessibility and capacity to penetrate into whole mount tissue specimens confines its reliability . Although, both techniques (fluorescent in-situ hybridization (FISH) and reverse transcriptase polymerase chain reaction (RT-PCR)) have inevitable advantages in the field of diagnostics but comparative evidence of more target specificity and sensitivity of RT-PCR for the detection of minimal residual disease in long-term monitoring of patients has increased its importance in some applications . In addition to that quantitative real time PCR which has ability to detect as low as two fold changes in the gene expression, is rapidly replacing immunological assays [27, 28]. Numerous therapeutic agents aiming EBV associated tumour regression are beginning to emerge [29, 30]. These targeted drug delivery systems induce viral lytic gene expression [30, 31] and therefore, require more sensitive quantitative analysis of viral as well as cellular gene expression to monitor the effect of these therapeutic treatments.
This study was aimed to develop a precise Real time PCR based laboratory methodology to detect and quantify EBV encoded RNAs in FFPE Burkit's lymphoma samples of Pakistani origin. Furthermore, anti-inflammatory cytokine (IL-10) expression in EBV+ (positive) samples were characterized to indicate its relevance with viral persistence in tumour cells. These studies will introduce novel potential biomarkers as well as new insight in the current diagnostic trends of Pakistan.
Sample Collection and Cell Culture
In total eight (8) lymphoma samples were included in this study. The sampling was conducted at Pakistan Institute of Medical Sciences (PIMS), for routine histopathological examination. Formalin Fixation and Paraffin Embedding (FFPE) procedures were then carefully performed [32–35] on lymphoma samples individually, under sterile conditions. After histopathological examination three (3) samples were classified as Burkitt's lymphoma (BL) and five (5) as non-Hodgkin lymphomas (NHLs).
EBV transformed B95-8 cell line (Kindly provided by Dr. Sharof Tugizov Department of Medicine, University of California, San Francisco, California USA) were maintained in RPMI 1640 supplemented with 10% fetal bovine serum (FBS), 1% L-glutamine, and 1% penicillin-streptomycin (all from Gibco, Basel, Switzerland).
Nucleic Acid Extraction and Purifications
Approximately 4 × 20 μm sections of selected samples were taken for nucleic acid extraction and purification. Genomic DNA was purified from Formalin-fixed Paraffin embedded tissue sections by using QIAamp DNA FFPE Tissue Kit (Qiagen).
Total RNA of the positive samples was extracted by using PureLink™ FFPE Total RNA Isolation Kit (Invitrogen Carlsbed, CA U.S.A) according to manufacturer instructions. All samples were treated with DNase I Amplification Grade (Invitrogen Carlsbed, CA U.S.A) to eliminate DNA contaminations.
Amplification and Detection
Before EBV specific amplifications, all DNA samples were tested with primers to amplify a fragment of the human β globin Genes in order to ensure DNA integrity. Initially, nested PCR based screening for EBV presence of all lymphoma samples were carried out by targeting genomic DNA of EBNA1 as recommended by Bagan JV et al, 2008 .
Specification of Primers used in RT-PCR and qRT-PCR Experiments
Primer Sequence 5'-----------------3'
EBV encoded RNA 1 (EBER1)
5'- AGGACCTACGCTGCCCTAGA -3'
5'- AAAACATGCGGACCACCAGCTGG -3'
EBV encoded RNA 2 (EBER2)
5'- AGGACAGCCGTTGCCCTAGTG -3'
5'- TAGCGGACAAGCCGAATACCCT -3'
Interleukin 10 (IL10), mRNA
5'- ATGCACAGCTCAGCACTGCTCTG -3'
5'- GGAAGAAATCGATGACAGCGCCG -3'
Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH), mRNA
5'- CAAGGTCATCCATGACAACTTTG -3'
5'- GTCCACCACCCTGTTGCTGTAG -3'
Quantitative Real time PCR (qRT-PCR)
Quantitative Real time PCR (qRT-PCR) of 10 ul of Total RNA template (50 ng) of EBV+ (positive) and EBV- (negative) samples were used to amplify EBER 1/EBER 2 and IL-10 aimed primers (Table 1). Thermocycling was performed at 95°C for 3 minutes, followed by 40 cycles at 94°C for 30 s, 54°C for 30 s, and 72°C for 40 s to measure the fluorescence signal. Quantitative analyses of the data were carried out using 7300 system SDS software v1.4 (Applied Biosystems, USA). Reaction concentrations and conditions were adjusted according to the manual instructions of SuperScript®III Platinum® SYBR® Green One-Step qRT-PCR Kit (Invitrogen Carlsbed, CA, U.S.A). Equal quantity of RNA from B95-8 cell line (Positive control) and EBV- tissue sample (Negative control) were used. All experiments were done in triplicate.
Purification and Sequencing
The amplified product was purified by using PureLink™ Gel Extraction Kit (Invitrogen Carlsbed, CA U.S.A) according to the manufacturer's instructions. The purified product was sequenced by using Genetic Analysis System Beckman Coulter (CEQ-8000 USA). These sequences were published in Genbank, EMBL and DDBJ [Accession Number: GU205106 & GU205107].
In a real time PCR assay Ct (cycle threshold) is defined as the number of cycles required by fluorescent signals to cross the threshold. Ct levels are inversely proportional to the quantity of target nucleic acid in the sample [37, 38].
In these experiments, the linear rates of expressions of EBER1, EBER2 and IL-10 were calculated by dividing the threshold (0.10) with respective mean CT values of EBV+ patients.
Expression of both viral RNA and cellular RNA are significantly high, in comparison with normal EBV- (negative) lymphoma tissues. These results suggested that RNA isolated from FFPE samples preserve the majority of the characteristic expression. In addition to that elevated expression of anti-inflammatory cytokine (IL-10) was observed in the EBV+ (positive) samples in comparison with EBV- samples (undetectable or negligibly low levels of expression) which indicate its relevance with viral persistence in EBV transformed tumour cells. These studies will open novel avenues to study cellular and/or viral gene expression and will introduce new biomarkers and strategies to improve clinical as well as diagnostic practices in Pakistan.
We thank Dr. Sharof Tugizov Department of Medicine, University of California, San Francisco, California USA for providing us B95-8 cell line and National University of Sciences and Technology (NUST), Sector H-12 Islamabad Pakistan, for proving us facilities for this research work.
This work was funded by the Higher Education Commission of Pakistan (HEC, R&D Grant Number 20-829/R&D/2006.
We appreciate help of Dr. Jamil, RCMS NUST in Real time PCR Data analysis.
- Epstein MA, Achong BG, Barr YM: Virus particles in cultured lymphoblasts from Burkitt's lymphoma. The Lancet. 1964, 1: 702-703.View ArticleGoogle Scholar
- zur Hausen A, Brink AA, Craanen ME, Middeldorp JM, Meijer CJ, van den Brule AJ: Unique transcription pattern of Epstein-Barr virus (EBV) in EBV-carrying gastric adenocarcinomas: expression of the transforming BARF1 gene. Cancer Res. 2000, 60: 2745-2748.PubMedGoogle Scholar
- Judde JG, Spangler G, Magrath I, Bhatia K: Use of Epstein Barr virus nuclear antigen-1 in targeted therapy of EBV-associated neoplasia. Hum Gene Ther. 1996, 7: 647-653. 10.1089/hum.1996.7.5-647.View ArticlePubMedGoogle Scholar
- Chang YS, Tyan YS, Liu ST, Tsai MS, Pao CC: Detection of Epstein-Barr virus DNA sequences in nasopharyngeal carcinoma cells by enzymatic DNA amplification. J Clin Microbiol. 1990, 28: 2398-2402.PubMed CentralPubMedGoogle Scholar
- Suzushima H, Asou N, Fujimoto T, Nishimura S, Okubo H, Yamasaki H, Osato M, Matsuoka M, Tsukamoto A, Takai K, Kawano F, Takatsuki K: Lack of the expression of EBNA-2 and LMP-1 in T-cell neoplasms possessing Epstein-Barr virus. Blood. 1995, 85: 480-486.PubMedGoogle Scholar
- Carlos VP, Fung JJ, Nalesnik MA, Kieff E, Green M, Gores G, Habermann TM, Wiesner RH, Swinnen LJ, Woodle ES, Bromberg JS: Epstein-barr virus-Induced Posttransplant Lymphoproliferative disorders. Transplantation. 1999, 68: 1517-1525. 10.1097/00007890-199911270-00015.View ArticleGoogle Scholar
- Carlos VP, Fung JJ, Nalesnik MA, Kieff E, Green M, Gores G, Habermann TM, Wiesner R, Swinnen LJ, Woodle ES, Bromberg JS: Epstein Barr Virus-Induced Posttransplant Lymphoproliferative Disorders (ptld). Transplantation. 1999, 68: 1517-1525. 10.1097/00007890-199911270-00015.View ArticleGoogle Scholar
- Mansoor A, Stevenson MS, Li RZ, Frekko K, Weiss W, Ahmad M, Khan AH, Mushtaq S, Saleem M, Raffeld M, Kingma DW, Jaffe ES: Prevalence of Epstein-Barr viral sequences and EBV LMP1 oncogene deletions in Burkitt's lymphoma from Pakistan: epidemiological correlations. Hum Pathol. 1997, 28: 283-288. 10.1016/S0046-8177(97)90125-8.View ArticlePubMedGoogle Scholar
- Lawrence SY, Rickinson AB: Epstein-Barr Virus: 40 Years On. Nature Reviews Cancer. 2004, 4: 757-768. 10.1038/nrc1452.View ArticleGoogle Scholar
- Rowe M, Rowe DT, Gregory CD, Young LS, Farrell PJ, Rupani H, Rickinson AB: Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J. 1987, 6: 2743-2751.PubMed CentralPubMedGoogle Scholar
- Wang F, Gregory C, Sample C, Rowe M, Liebowitz D, Murray R, Rickinson A, Kieff E: Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol. 1990, 64: 2309-2318.PubMed CentralPubMedGoogle Scholar
- Lawrence SY, Murray PG: Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene. 2003, 22: 5108-5121. 10.1038/sj.onc.1206556.View ArticleGoogle Scholar
- Takada K, Nanbo A: The role of EBERs in oncogenesis. Cancer Biology. 2001, 11: 461-467. 10.1006/scbi.2001.0413.View ArticleGoogle Scholar
- Kube D, Platzer C, von Knethen A, Straub H, Bohlen H, Hafner M, Tesch H: Isolation of the humen interleukin 10 promoter. Characterization of the promoter activity in Burkitt's lymphoma cell lines. Cytokine. 1995, 7: 1-7. 10.1006/cyto.1995.1001.View ArticlePubMedGoogle Scholar
- Norihiko K, Goto M, Kurozumi K, Maruo S, Fukayama M, Naoe T, Yasukawa M, Hino K, Suzuki T, Todo S, Takada K: Epstein ± Barr virus-encoded poly(A) ± RNA supports Burkitt's lymphoma growth through interleukin-10 induction. The EMBO Journal. 2000, 19: 6742-6750. 10.1093/emboj/19.24.6742.View ArticleGoogle Scholar
- Vockerodt M, Haier B, Buttgereit P, Tesch H, Kube D: The Epstein ± Barr Virus Latent Membrane Protein 1 Induces Interleukin-10 in Burkitt's Lymphoma Cells but Not in Hodgkin's Cells Involving the p38/SAPK2 Pathway. Virology. 2001, 280: 183-198. 10.1006/viro.2000.0768.View ArticlePubMedGoogle Scholar
- Samanta M, Iwakiri D, Takada K: Epstein-Barr virus-encoded small RNA induces IL-10 through RIG-I-mediated IRF-3 signaling. Oncogene. 2008, 27: 4150-4160. 10.1038/onc.2008.75.View ArticlePubMedGoogle Scholar
- Fok V, Friend K, Steitz JA: Epstein-Barr virus noncoding RNAs are confined to the nucleus, whereas their partner, the human La protein, undergoes nucleocytoplasmic shuttling. The Journal of Cell Biology. 2006, 173: 319-325. 10.1083/jcb.200601026.PubMed CentralView ArticlePubMedGoogle Scholar
- Lewis F, Maughan NJ, Smith V, Hillan K, Quirke P: Unlocking the archive-gene expression in paraffin-embedded tissue. J Pathol. 2001, 195: 66-71. 10.1002/1096-9896(200109)195:1<66::AID-PATH921>3.0.CO;2-F.View ArticlePubMedGoogle Scholar
- Gulley ML: Molecular diagnosis of Epstein-Barr virus-related diseases. J Mol Diagn. 2001, 3: 1-10. 10.1016/S1525-1578(10)60642-3.PubMed CentralView ArticlePubMedGoogle Scholar
- Ambinder RF, Mann RB: Detection and characterization of Epstein-Barr virus in clinical specimens. Am J Pathol. 1994, 145: 239-252.PubMed CentralPubMedGoogle Scholar
- Fanaian NK, Cohen C, Waldrop S, Wang J, Shehata BM: Epstein-Barr virus (EBV)-encoded RNA: automated in-situ hybridization (ISH) compared with manual ISH and immunohistochemistry for detection of EBV in pediatric lymphoproliferative disorders. Pediatr Dev Pathol. 2009, 3: 195-199.View ArticleGoogle Scholar
- Margaret LG, Glaser SL, Craig FE, Borowitz M, Mann RB, Shema SJ, Ambinder RF: Guidelines for Interpreting EBER In Situ Hybridization and LMP1 Immunohistochemical Tests for Detecting Epstein-Barr Virus in Hodgkin Lymphoma. Am J Clin Pathol. 2002, 117: 259-267. 10.1309/MMAU-0QYH-7BHA-W8C2.View ArticleGoogle Scholar
- Vera-Sempere FJ, Burgos JS, Botella MS, Cordoba J, Gobernado M: Immunohistochemical Expression of Epstein-Barr Virus-encoded Latent Membrane Protein (LMP-1) in Paraffin Sections of EBV-associated Nasopharyngeal Carcinoma in Spanish Patients. Oral Oncol, EurJ Cancer. 1996, 163-168. 32BGoogle Scholar
- Smith A, Zhang J, Guay D, Quint E, Johnson A, Akimenko MA: Gene Expression Analysis on Sections of Zebrafish Regenerating Fins Reveals Limitations in the Whole-Mount In Situ Hybridization Method. Developmental Dynamics. 2008, 237: 417-425. 10.1002/dvdy.21417.View ArticlePubMedGoogle Scholar
- Polampalli S, Choughule A, Prabhash K, Amare P, Baisane C, Kabre S, Mahadik S, Shinde S, Nair R, Banavali S: Role of RT-PCR and FISH in diagnosis and monitoring of acute promyelocytic leukemia. Indian Journal of Cancer. 2011, 48: 60-67. 10.4103/0019-509X.75831.View ArticlePubMedGoogle Scholar
- Lorenzo D, Lombardi A, Vecchi ED, Giuliani G, Bartolone R, Gismondo MR: Comparison of nested PCR and real time PCR of Herpesvirus infections of central nervous system in HIV patients. BMC Infectious Diseases. 2004, 4: 55-10.1186/1471-2334-4-55.View ArticleGoogle Scholar
- Ruiz G, Penña P, de Ory F, Echevarría JE: Comparison of Commercial Real-Time PCR Assays for Quantification of Epstein-Barr Virus DNA. Journal of Clinical Microbiology. 2005, 43: 2053-2057. 10.1128/JCM.43.5.2053-2057.2005.PubMed CentralView ArticlePubMedGoogle Scholar
- Jabbour E, Cortes JE, Ghanem H, O'Brien S, Kantarjian HM: Targeted therapy in chronic myeloid leukemia. Expert Rev Anticancer Ther. 2008, 8: 99-110. 10.1586/14737184.108.40.206.View ArticlePubMedGoogle Scholar
- De-Xue F, Yvette T, Jianmeng C, Catherine AF, James JF, Ja-Mun C, Robert FH, Masashi F, George S, Jeanne K, Martin GP, Richard FA: Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors. Nature Medicine. 2008, 14: 1118-1122. 10.1038/nm.1864.View ArticleGoogle Scholar
- De-Xue F, Yvette CT, Jianmeng C, Catherine AF, James JF, Victor L, Ja-Mun C, Richard FA, Martin GP: Virus-Associated Tumor Imaging by Induction of Viral Gene Expression. Clin Cancer Res. 2007, 13: 1453-1458. 10.1158/1078-0432.CCR-06-2295.View ArticleGoogle Scholar
- von Ahlfen S, Andreas M, Bendrat K, Schlumpberger KM: Determinants of RNA Quality from FFPE Samples. PLoS ONE. 2007, 2: e1261-10.1371/journal.pone.0001261.PubMed CentralView ArticlePubMedGoogle Scholar
- Masuda N, Ohnishi T, Kawamoto S, Monden M, Okubo K: Analysis of chemical modification of RNA from formalin-fixed samples and optimization of molecular biology applications for such samples. Nucleic Acids Res. 1999, 27: 4436-4443. 10.1093/nar/27.22.4436.PubMed CentralView ArticlePubMedGoogle Scholar
- Bresters D, Schipper MEI, Reesink HW, Boeser-Nunnink BDM, Cuypers HTM: The Duration of Fixation Influences the Yield of HCV cDNA-PCR Products from Formalin-Fixed, Paraffin-Embedded Tissue. J Virol Methods. 1994, 48: 267-272. 10.1016/0166-0934(94)90125-2.View ArticlePubMedGoogle Scholar
- Macabeo-Ong M, Ginzinger DG, Dekker N, McMillan A, Regezi JA, Wong DT, Jordan RC: Effect of duration of fixation on quantitative reverse transcription polymerase chain reaction analyses. Mod Pathol. 2002, 15: 979-987. 10.1097/01.MP.0000026054.62220.FC.View ArticlePubMedGoogle Scholar
- Bagan JV, Jiménez Y, Murillo J, Poveda R, Diaz JM, Gavaldá C, Margaix M, Scully C, Alberola TM, Puente MT, Alonso MP: Epstein-Barr virus in oral proliferative verrucous leukoplakia and squamous cell carcinoma: A preliminary study. Med Oral Patol Oral Cir Bucal. 2008, 13: 110-3.Google Scholar
- Real-time PCR: Understanding Ct. [http://www3.appliedbiosystems.com/cms/groups/mcb_marketing/documents/generaldocuments/cms_053906.pdf]
- Applied Biosystems 7300/7500 Fast Real-Time PCR System Standard Curve Experiments: Getting started guide. P.N. 4387779 Rev. C. [http://www3.appliedbiosystems.com/cms/groups/mcb_support/documents/generaldocuments/cms_050329.pdf]
- Lewis RS, Ward AC: Stat5 as a diagnostic marker for leukemia. Expert Rev Mol Diagn. 2008, 8: 73-82. 10.1586/14737220.127.116.11.View ArticlePubMedGoogle Scholar
- Carella AM, Lerma E: Imatinib mesylate in chronic myeloid leukemia. Curr Stem Cell Res Ther. 2007, 2: 249-51. 10.2174/157488807781696276.View ArticlePubMedGoogle Scholar
- Pal SK, Pegram M: HER2 targeted therapy in breast cancer...beyond Herceptin. Rev Endocr Metab Disord. 2007, 8: 269-77. 10.1007/s11154-007-9040-6.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.